NRIX | tickerfilter.com

Fundamental analysis

45%

Profitability 43%

Dept financing 24%

Liquidity 58%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.40%

1 Month

16.43%

3 Months

-2.90%

6 Months

45.98%

1 Year

49.30%

2 Year

36.97%

Key data

Stock price

$17.08

P/E Ratio

0.00

DAY RANGE

$16.51 - $17.49

EPS

-$3.17

52 WEEK RANGE

$8.20 - $22.50

52 WEEK CHANGE

$48.14

MARKET CAP

1.642 B

YIELD

N/A

SHARES OUTSTANDING

103.406 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-10-2025

BETA

2.07

PUBLIC FLOAT

AVERAGE 10 VOLUME

$764,682

AVERAGE 30 VOLUME

$1,123,890

Company detail

CEO: Arthur T. Sands
Region: US
Website: nurixtx.com
Employees: 300
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.

NRIX - Nurix Therapeutics, Inc.